Fulcrum Therapeutics, Inc. Share Price & Technical Analysis
FULC · $6.57 (-0.30%)
Healthcare / Biotechnology
$6.57
-0.30%
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassem…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-7% return in May, 33% avg return in past 3 year May month.
-50% return in 2026, 77% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -6% | -22% | -6% | -9% | -7% | – | – | – | – | – | – | – | -50% |
| 25 | -17% | -5% | -19% | 31% | 82% | -1% | 0% | -2% | 44% | -5% | 25% | 5% | 137% |
| 24 | 9% | 40% | -9% | -25% | 8% | -22% | 50% | -9% | -58% | -11% | 19% | 24% | 16% |
| 23 | 70% | -52% | -54% | -14% | 8% | 22% | 15% | 45% | -20% | -18% | 33% | 42% | 77% |
| 22 | -32% | -8% | 117% | -60% | -25% | -33% | 20% | 25% | 8% | -31% | 19% | 7% | 9% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$460.44M
P/E ratio
—
52W high
$15.74
52W low
$5.88
Volume
2,93,653
Beta
3.01
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Fulcrum Therapeutics, Inc. share price today?
- Fulcrum Therapeutics, Inc. (FULC) last traded around $6.57 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does FULC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for FULC. Download the app for real-time alerts.
- How can I analyze Fulcrum Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.